Research And Application Of The Recombinant Human Erythropoietin About Neuroprotection Of Patients With Craniocerebral Injury

ObjectiveTo explore the effect of recombinant human erythropoietin(rhEPO)for theneuroprotection in patients with craniocerebral Injury and its clinical application.MethodsWe selected80cases of ICU patients with craniocerebral injury,the50caseswere chosed from80cases as the standard data were divided randomly into rhEPOgroup with30cases and control group with20cases.The rhEPO group washospitalized and treated,besides conventional treatment,with10000IU/time of therhEPO by the subcutaneous injection in the third, sixth, ninth and twelfth day. Thecontrol group was given with the conventional treatment only.The neuroglobin,hemoglobin, c-reactive protein values, APACHE Ⅱ scores, GCS scores and theirventilation time were assessed on the day in hospital and the fourth day, seventh day,tenth day, fourteenth day after they had been in the hospital. All the data was analyzedwith SPSS19.0statistical software. The statistical methods were analysis of varianceof repeated measurement data. ResultsThe neuroglobin in the experimental group was higher than the control groupthat was with statistical difference(Fgroup=9.979,P<0.05;Ftime=11.56,P<0.01);Thehemoglobin in the experimental group was higher than the control group that waswith statistical difference(Fgroup=20.26,P<0.01;Ftime=22.34,P<0.01);The APACHE Ⅱscore in the experimental group was lower than the control group that was withstatistical difference(Fgroup=9.339,P<0.05;Ftime=13.749,P<0.01);The ventilation timein the experimental group was shorter than the control group that was with statisticaldifference(P<0.05).GCS score increased with treatment,but with no statisticaldifference(Fgroup=2.679,P>0.05;Ftime=3.796,P<0.05).Before and after treating, Creactive protein expression in patients of the rhEPO group and the control group hadno significant change, no statistical difference(Fgroup=0.431，P>0.05;Ftime=1.123,P>0.05).In the patients with craniocerebral injury,the rhEPOusing could promote the expression of neuroglobin,promote the expression ofhemoglobin,and meanwhile could make APACHE Ⅱ score decrease and shortenventilation time,but there were no the effects on the expression of CRP and GCSscores.Conclusions1.The rhEPO using could promote the expression of neuroglobin.2.Exogenous application of rhEPO could play a protective effect in patients withcraniocerebral injury which provided experimental basis for clinical application.